Literature DB >> 10979670

Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reavtion identifies also patients with B-precursor acute lymphoblastic leukemia at high risk for relapse.

V de Haas, W B Breunis, O J Verhagen, H van der Berg, C E van der Schoot.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 10979670

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  4 in total

1.  Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01.

Authors:  Jianbiao Zhou; Meredith A Goldwasser; Aihong Li; Suzanne E Dahlberg; Donna Neuberg; Hongjun Wang; Virginia Dalton; Kathryn D McBride; Stephen E Sallan; Lewis B Silverman; John G Gribben
Journal:  Blood       Date:  2007-05-07       Impact factor: 22.113

2.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Authors:  Michael J Borowitz; Meenakshi Devidas; Stephen P Hunger; W Paul Bowman; Andrew J Carroll; William L Carroll; Stephen Linda; Paul L Martin; D Jeanette Pullen; David Viswanatha; Cheryl L Willman; Naomi Winick; Bruce M Camitta
Journal:  Blood       Date:  2008-04-03       Impact factor: 22.113

3.  Flow cytometric chemosensitivity assay as a predictive tool of early clinical response in acute lymphoblastic leukemia.

Authors:  Faith Galderisi; Linda Stork; Ju Li; Motomi Mori; Solange Mongoue-Tchokote; James Huang
Journal:  Pediatr Blood Cancer       Date:  2009-10       Impact factor: 3.167

4.  Mitochondrial DNA in residual leukemia cells in cerebrospinal fluid in children with acute lymphoblastic leukemia.

Authors:  Kathryn Egan; Ian Kusao; David Troelstrup; Melissa Agsalda; Bruce Shiramizu
Journal:  J Clin Med Res       Date:  2010-10-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.